Exciting news! We exceeded our Q2 2025 outlook with solid growth and improved profitability. Learn more 👉

◾ 2025 net sales outlook increased to +4-5% CER (prior about +4% CER) and +5-6% CER core sales (prior about +5% CER); adj. diluted EPS outlook reaffirmed for about $2.35 CER.

➡ Diagnostic solutions sales +11% CER, driven by QIAstat-Dx (+41% CER) and QuantiFERON (+11% CER) and companion diagnostic partnerships.

➡ 29.9% adj. operating income margin up 1.5 percentage points vs. 28.4% in Q2 2024.

➡ Net sales +6% CER (constant exchange rates) above outlook for at least +5% CER and adjusted diluted EPS of $0.62 CER above outlook for at least $0.60 CER.

◾ Q2 2025 results: Net sales of $534 million (+7% actual rates); adjusted diluted EPS of $0.60.

Think all healthy guts look the same? Not even close. In Southeast Asia, AMILI is building a gut microbiome bank just for the region, with help from QIAGEN’s EZ2 PowerFecal Pro Kit, to make healthcare more local and more personal. See how 👉

We’re growing our NGS portfolio with the new QIAseq xHYB Long Read Panels, making it easier to explore even the most complex genomic regions using native long-read sequencing. Learn more 👉

🎉 We are humbled to share that QIAGEN has again been recognized as one of the Best Places to Work for Disability Inclusion in both the United States and Germany. 👏 Thank you to our QIAGENers who foster a culture of inclusion, accessibility, and respect every day.

🔎 It could be hiding in plain sight. Have you checked your QIAGEN red and blue boxes lately? A cool collectible might be hiding in plain sight. 🎯 If you spot it, scan the QR code and unlock next-level precision for your research. #DigitalPCR #dPCR

We are excited to announce a new strategic global partnership with GENCURIX, a leading diagnostics company specializing in oncology, to jointly develop and commercialize digital PCR-based oncology diagnostic products. Learn more 👉

We’re partnering with @Incyte to develop a companion diagnostic panel for patients with mutant CALR-expressing myeloproliferative neoplasms (MPNs), a group of rare blood cancers. Learn more 👉

We’re expanding our oncology diagnostics portfolio with two new strategic partnerships focused on advancing minimal residual disease (MRD) testing in clinical trials — supporting pharma co-development for future companion diagnostics. Learn more 👉

We are excited to announce that @GenooxTeam , a provider of AI-powered software that enables clinical labs to scale and accelerate the processing of complex genetic tests, has joined @QIAGEN. Learn more 👉

◾ 2025 outlook reaffirmed for about 4% CER sales growth (about +5% CER core sales growth); recently increased adj. diluted EPS outlook reaffirmed for about $2.35 CER.

◾ Stephen H. Rusckowski proposed to become new Chairman of Supervisory Board as Lawrence A. Rosen chooses to step down from Board after upcoming AGM.

◾ Proposal at Annual General Meeting to introduce a dividend as expansion of capital allocation strategy, also seek authorization for a new $500 million share repurchase.

➡ Operating cash flow of $140 million in Q1 2025 vs. $133 million in Q1 2024.

➡ 29.8% adj. operating income margin up 4.1 percentage points vs. 25.7% in Q1 2024.

➡ Net sales growth of +7% CER ahead of outlook for about +3% CER growth and adjusted diluted EPS of $0.56 CER ahead of outlook for at least $0.50 CER.